European Heart Journal Advance Access published online on May 26, 2006
European Heart Journal, doi:10.1093/eurheartj/ehl053
1 Centre for Pharmacotherapy Development and Postgraduate School of Clinical Drug Research, University of Turku, PB 55, FIN-00301 Helsinki, Finland
* To whom correspondence should be addressed. Aims To evaluate the risk of first myocardial infarction (MI) associated with the use of various non-steroidal anti-inflammatory drugs (NSAIDs) in the general population. Methods and results We conducted a population-based matched case-control study over the years 2000-3 in outpatient residents of Finland. In the nationwide Hospital Discharge Register 33 309 persons with first time MI were identified. A total of 138 949 controls individually matched for age, gender, hospital catchment area, and index day were selected from the Population Register. For combined NSAIDs, the adjusted odds ratio for the risk of first MI with current use was 1.40 (95% CI, 1.33-1.48). The risk was similar for conventional (1.34; 1.26-1.43), semi-selective (etodolac, nabumetone, nimesulide, and meloxicam) (1.50; 1.32-1.71), and cyclo-oxygenase-2 (COX-2) selective NSAIDs (rofecoxib, celecoxib, valdecoxib, and etoricoxib) (1.31; 1.13-1.50). Age of current user did not consistently modify the risk. No NSAID was associated with an MI-protective effect. All durations from 1 to 180 days of conventional NSAIDs and from 31 to 90 days duration of COX-2 selective NSAIDs were associated with an elevated risk of MI. Conclusion Current use of all NSAIDs is associated with a modest risk of first time MI.
Received February 20, 2006
Revised May 4, 2006
Accepted May 6, 2006
Clinical research
NSAID use and the risk of hospitalization for first myocardial infarction in the general population: a nationwide case-control study from Finland
Arja Helin-Salmivaara 1 *,
Arja Virtanen 2,
Risto Vesalainen 3,
Juha M. Grönroos 4,
Timo Klaukka 5,
Juhana E. Idänpään-Heikkilä 6,
and
Risto Huupponen 7
2 Research Department, Social Insurance Institution, Peltolantie 2, FIN-20720 Turku, Finland
3 Department of Medicine, Turku University Hospital, PB 52, FIN-20521 Turku, Finland
4 Department of Emergency, Turku University Hospital and Department of Surgery, University of Turku, PB 52, FIN-20521 Turku, Finland
5 Research Department, Social Insurance Institution, PB 450, FIN-00101 Helsinki, Finland
6 Council for International Organizations of Medical Sciences, c/o WHO, CH-1211, Geneva 27, Switzerland
7 Department of Pharmacology and Clinical Pharmacology, University of Turku and Department of Pharmacology and Toxicology, University of Kuopio and Kuopio University Hospital, PB 1627, FIN-70211 Kuopio, Finland
Arja Helin-Salmivaara, E-mail: arja.helin-salmivaara{at}rohto.fi
Abstract 
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  I. T. Padol and R. H. Hunt Association of myocardial infarctions with COX-2 inhibition may be related to immunomodulation towards a Th1 response resulting in atheromatous plaque instability: an evidence-based interpretation Rheumatology, September 24, 2009; (2009) kep225v1. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Chilet-Rosell, M. T. Ruiz-Cantero, and J. F. Horga Women's health and gender-based clinical trials on etoricoxib: methodological gender bias J. Public Health Med., September 1, 2009; 31(3): 434 - 445. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. H. Gislason, J. N. Rasmussen, S. Z. Abildstrom, T. K. Schramm, M. L. Hansen, E. L. Fosbol, R. Sorensen, F. Folke, P. Buch, N. Gadsboll, et al. Increased Mortality and Cardiovascular Morbidity Associated With Use of Nonsteroidal Anti-inflammatory Drugs in Chronic Heart Failure Arch Intern Med, January 26, 2009; 169(2): 141 - 149. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P A Scott, G H Kingsley, C M Smith, E H Choy, and D L Scott Non-steroidal anti-inflammatory drugs and myocardial infarctions: comparative systematic review of evidence from observational studies and randomised controlled trials Ann Rheum Dis, October 1, 2007; 66(10): 1296 - 1304. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Salinas, U. C. Rangasetty, B. F. Uretsky, and Y. Birnbaum The Cycloxygenase 2 (COX-2) Story: It's Time to Explain, Not Inflame Journal of Cardiovascular Pharmacology and Therapeutics, June 1, 2007; 12(2): 98 - 111. [Abstract] [PDF]
|
|
|
|
 |
|
 D. J. Graham COX-2 Inhibitors, Other NSAIDs, and Cardiovascular Risk: The Seduction of Common Sense JAMA, October 4, 2006; 296(13): 1653 - 1656. [Full Text] [PDF]
|
|